Compare KSCP & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KSCP | RNTX |
|---|---|---|
| Founded | 2013 | 2001 |
| Country | United States | United States |
| Employees | N/A | 10 |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.1M | 47.7M |
| IPO Year | 2022 | N/A |
| Metric | KSCP | RNTX |
|---|---|---|
| Price | $3.44 | $1.78 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $17.00 | $10.00 |
| AVG Volume (30 Days) | ★ 867.9K | 118.7K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.54 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,335,000.00 | N/A |
| Revenue This Year | $218.66 | N/A |
| Revenue Next Year | $54.32 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 4.91 | N/A |
| 52 Week Low | $2.92 | $1.02 |
| 52 Week High | $10.13 | $2.22 |
| Indicator | KSCP | RNTX |
|---|---|---|
| Relative Strength Index (RSI) | 43.12 | 68.65 |
| Support Level | $3.09 | $1.08 |
| Resistance Level | $4.50 | $2.18 |
| Average True Range (ATR) | 0.34 | 0.19 |
| MACD | -0.05 | 0.04 |
| Stochastic Oscillator | 17.24 | 81.65 |
Knightscope Inc is a security technology company based in Silicon Valley. It designs, develops, manufactures, markets, and supports Autonomous Security Robots (ASRs), autonomous charging stations, the proprietary Knightscope Security Operations Center software user interface, Emergency Communication Devices platform with real-time on-site data collection and analysis and a proprietary interface for both indoor and outdoor usage. In addition, it developed and operates the Knightscope Security Operations Center (KSOC) which allows real-time data access, a service accessible to all its clients.
Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.